We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Pharma Tech Trends and Development Cost Solutions

Read time: Less than a minute

The free webinar lays out the pressures currently being faced by the industry—including cost and regulatory pressures—and explores the chemistry workflows and emerging technologies that are helping industry participants address these challenges, remain competitive, and protect profits.

With the reality of patent cliffs, regulatory standards, attrition, and globalization, companies are learning to work fast and “lean” without sacrificing effectiveness and safety. In the webinar, targeted technology application and the methodologies it enables results in an ability to handle increased experiment volume—the kind that will be required for success if pharmaceutical industry trends continue—while lowering development and production costs.

Accounting for issues such as inherited chemistry, variable yields, and long development cycles, the webinar looks at real-world examples of industry giants such as Pfizer using technologies that help understand particle and reaction characteristics for significant process enhancement. In situ mid-IR spectroscopy and Focus Beam Reflectance Measurement (FBRM®)—as well as workstations that incorporate them—are shown to illuminate particle growth/crystallization and other critical reaction characteristics to shorten cycle times, increase yields, enhance safety, and ease scale-up. One production initiation example lowered costs by at least $.5M—a savings that will compound with each successive use of the equipment.

Reaction Progress Kinetics Analysis is also discussed in detail. This methodology, developed by Professor Donna Blackmond who is currently with Scripps Research Institute, allowed researchers to develop a kinetic model in significantly fewer experiments over traditional methods, which in turn helped optimize a synthetic route for enhanced commercial viability.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.